相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers
Swathi Merugu et al.
CLINICAL CANCER RESEARCH (2020)
Preclinical models for neuroblastoma: Advances and challenges
J. C. Nolan et al.
CANCER LETTERS (2020)
Update on neuroblastoma
Erika A. Newman et al.
JOURNAL OF PEDIATRIC SURGERY (2019)
Childhood cancer incidence and survival in Thailand: A comprehensive population-based registry analysis, 1990-2011
Serena S. Bidwell et al.
PEDIATRIC BLOOD & CANCER (2019)
MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53
Wei Wang et al.
CANCER LETTERS (2019)
The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy
Yao Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
MDM2-p53 Interaction inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)
Rafal Rusiecki et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2019)
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma
Sara Gomes et al.
CANCER LETTERS (2019)
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma
Lindi Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Neuroblastoma: An Updated Review on Biology and Treatment
Suresh Mallepalli et al.
CURRENT DRUG METABOLISM (2019)
Reactivating TP53 signaling by the novel MDM2 inhibitor DS3032b as a therapeutic option for high-risk neuroblastoma
Viktor Arnhold et al.
ONCOTARGET (2018)
Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms
Wei Wang et al.
CARCINOGENESIS (2018)
Neuroblastoma: clinical and biological approach to risk stratification and treatment
Vanessa P. Tolbert et al.
CELL AND TISSUE RESEARCH (2018)
An Update on MDMX and Dual MDM2/X Inhibitors
Margarida Espadinha et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2018)
Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy
Jiang-Jiang Qin et al.
FRONTIERS IN PHARMACOLOGY (2018)
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy
Wei Wang et al.
CANCER RESEARCH (2018)
QSAR studies of new pyrido[3,4-b]indole derivatives as inhibitors of colon and pancreatic cancer cell proliferation
Hemantkumar Deokar et al.
MEDICINAL CHEMISTRY RESEARCH (2018)
Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine
Jiang-Jiang Qin et al.
GENES & DISEASES (2018)
Biological and Genetic Features of Neuroblastoma and their Clinical Importance
Nevim Aygun
CURRENT PEDIATRIC REVIEWS (2018)
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
Veronica Tisato et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Computer-Aided Identification and Lead Optimization of Dual Murine Double Minute 2 and 4 Binders: Structure-Activity Relationship Studies and Pharmacological Activity
Mariateresa Giustiniano et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
Alan Van Goethem et al.
ONCOTARGET (2017)
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
Hui Qin Wang et al.
ELIFE (2017)
Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein
Xiaoguang Li et al.
CELL DISCOVERY (2017)
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy
Myrthala Moreno-Smith et al.
CLINICAL CANCER RESEARCH (2017)
Trends in incidence, survival and mortality of childhood and adolescent cancer in Austria, 1994-2011
Henrike E. Karim-Kos et al.
CANCER EPIDEMIOLOGY (2016)
Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis
Jiang-Jiang Qin et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review
F. Peinemann et al.
KLINISCHE PADIATRIE (2016)
Initial Testing (Stage 1) of MK-8242A Novel MDM2 Inhibitorby the Pediatric Preclinical Testing Program
Min H. Kang et al.
PEDIATRIC BLOOD & CANCER (2016)
Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance
Yvonne Voges et al.
CELL DEATH & DISEASE (2016)
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Joonil Jung et al.
NATURE COMMUNICATIONS (2016)
Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma
Jiaxiong Lu et al.
ONCOTARGET (2016)
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
Jiang-Jiang Qin et al.
ONCOTARGET (2016)
Clinical Overview of MDM2/X-Targeted Therapies
Andrew Burgess et al.
FRONTIERS IN ONCOLOGY (2016)
Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy
Jiang-Jiang Qin et al.
JOURNAL OF BIOMEDICAL RESEARCH (2016)
TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma
Abdelkader Selmi et al.
CANCER LETTERS (2015)
Incidence, mortality and survival of childhood cancer in China during 2000-2010 period: A population-based study
Rongshou Zheng et al.
CANCER LETTERS (2015)
Advances in Risk Classification and Treatment Strategies for Neuroblastoma
Navin R. Pinto et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival
Lauren A. Gillory et al.
JOURNAL OF SURGICAL RESEARCH (2015)
Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment
C. Gianna Hoffman-Luca et al.
PLOS ONE (2015)
Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis
S. Nicolai et al.
CELL DEATH & DISEASE (2015)
Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA
Jiang-Jiang Qin et al.
ONCOTARGET (2015)
Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
Lindi Chen et al.
ONCOTARGET (2015)
Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation
Jiang-Jiang Qin et al.
ONCOTARGET (2015)
Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen
Martin Michaelis et al.
SCIENTIFIC REPORTS (2015)
The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma
A. Lakoma et al.
CELL DEATH DISCOVERY (2015)
Childhood and adolescent cancer statistics, 2014
Elizabeth Ward et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Childhood cancer survival in France, 2000-2008
Brigitte Lacour et al.
EUROPEAN JOURNAL OF CANCER PREVENTION (2014)
Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice
Wei Wang et al.
GASTROENTEROLOGY (2014)
Aurora Kinases as Targets in Drug-Resistant Neuroblastoma Cells
Martin Michaelis et al.
PLOS ONE (2014)
The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models
Wei Wang et al.
NATURE COMMUNICATIONS (2014)
Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis
M. Janaki Ramaiah et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Dual Targeting of Wild-Type and Mutant p53 by Small Molecule RITA Results in the Inhibition of N-Myc and Key Survival Oncogenes and Kills Neuroblastoma Cells In Vivo and In Vitro
Mikhail Burmakin et al.
CLINICAL CANCER RESEARCH (2013)
Japonicone A Suppresses Growth of Burkitt Lymphoma Cells through Its Effect on NF-κB
Xiaoguang Li et al.
CLINICAL CANCER RESEARCH (2013)
Berberine represses DAXX gene transcription and induces cancer cell apoptosis
Jiansha Li et al.
LABORATORY INVESTIGATION (2013)
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh et al.
NATURE GENETICS (2013)
Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop
X. Zhang et al.
ONCOGENE (2013)
The MDM2-p53 pathway revisited
Subhasree Nag et al.
JOURNAL OF BIOMEDICAL RESEARCH (2013)
Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
J. -J. Qin et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Transcription Factor NFAT1 Activates the mdm2 Oncogene Independent of p53
Xu Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells
L. Gu et al.
ONCOGENE (2012)
MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
L. D. Gamble et al.
ONCOGENE (2012)
Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells
Veronica Veschi et al.
PLOS ONE (2012)
Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents
M. Michaelis et al.
CELL DEATH & DISEASE (2012)
Animal models of extracranial pediatric solid tumors (Review)
Guido Seitz et al.
ONCOLOGY LETTERS (2012)
Ginsenosides as anticancer agents: in vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action
Subhasree Ashok Nag et al.
FRONTIERS IN PHARMACOLOGY (2012)
SMolecular mechanisms of MYCN-dependent apoptosis and the MDN2-p53 pathway: an Achillei's heel to be exploited for the therapy of MYCN-amplified neuroblastoma
Marialaura Petroni et al.
FRONTIERS IN ONCOLOGY (2012)
Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma
Danielle M. Patterson et al.
ANGIOGENESIS (2011)
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention
Susan K. Peirce et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma
Jing He et al.
CELL CYCLE (2011)
MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas
Ruimin Huang et al.
FASEB JOURNAL (2011)
MDM2 Regulates Vascular Endothelial Growth Factor mRNA Stabilization in Hypoxia
Sheng Zhou et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells
M. Michaelis et al.
CELL DEATH & DISEASE (2011)
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action
Wei Wang et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma
Jane Carr-Wilkinson et al.
CLINICAL CANCER RESEARCH (2010)
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer
Feng Wang et al.
INVESTIGATIONAL NEW DRUGS (2010)
Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bβ and TSLC1 in neuroblastoma
H. Ochiai et al.
ONCOGENE (2010)
Regulation of XIAP Translation and Induction by MDM2 following Irradiation
Lubing Gu et al.
CANCER CELL (2009)
Cytotoxic diarylheptanoid induces cell cycle arrest and apoptosis via increasing ATF3 and stabilizing p53 in SH-SY5Y cells
Ze Tian et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action
Wei Wang et al.
CANCER LETTERS (2009)
Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3
Martin Michaelis et al.
CANCER RESEARCH (2009)
Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2
Chihiro Ohtsubo et al.
CANCER SCIENCE (2009)
Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis
T. Van Maerken et al.
CELL DEATH AND DIFFERENTIATION (2009)
In vitro and In vivo Anticancer Activity of Novel Synthetic Makaluvamine Analogues
Wei Wang et al.
CLINICAL CANCER RESEARCH (2009)
RYBP stabilizes p53 by modulating MDM2
Deng Chen et al.
EMBO REPORTS (2009)
Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy
Tao Chen et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53
Tom Van Maerken et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Targeted Molecular Therapy for Neuroblastoma: The ARF/MDM2/p53 Axis
Eugene Kim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Anti-lung cancer effects of novel ginsenoside 25-OCH3-PPD
Wei Wang et al.
LUNG CANCER (2009)
Synthesis and In Vitro Anti-Lung Cancer Activity of Novel 1, 3, 4, 8-Tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-o ne Alkaloid Analogs
Dwayaja H. Nadkarni et al.
MEDICINAL CHEMISTRY (2009)
20(S)-25-methoxyl-dammarane-3β,12β,20-triol, a novel natural product for prostate cancer therapy:: activity in vitro and in vivo and mechanisms of action
W. Wang et al.
BRITISH JOURNAL OF CANCER (2008)
Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness:: Results of a pilot study on 239 patients
Sara Cattelani et al.
CLINICAL CANCER RESEARCH (2008)
Experimental therapy of hepatoma with artemisinin and its derivatives:: In vitro and in vivo activity, chemosensitization, and mechanisms of action
Junmei Hou et al.
CLINICAL CANCER RESEARCH (2008)
Proteasome activator PA28γ regulates p53 by enhancing its MDM2-mediated degradation
Zhuo Zhang et al.
EMBO JOURNAL (2008)
Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides
Wei Wang et al.
PROSTATE (2008)
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
L. M. S. Lau et al.
ONCOGENE (2008)
The pediatric preclinical testing program: Description of models and early testing results
Peter J. Houghton et al.
PEDIATRIC BLOOD & CANCER (2007)
P53 determines multidrug sensitivity of childhood neuroblastoma
Chengyuan Xue et al.
CANCER RESEARCH (2007)
p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma
Lindi Chen et al.
CELL CYCLE (2007)
Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function
D. Chen et al.
ONCOGENE (2007)
Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma
K. Becker et al.
CELL DEATH AND DIFFERENTIATION (2007)
N-MYC regulates focal adhesion kinase expression in human neuroblastoma
Elizabeth A. Beierle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng
Wei Wang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
p14ARF interacts with N-Myc and inhibits its transcriptional activity
Stefano Amente et al.
FEBS LETTERS (2007)
Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway
Mao Li et al.
CANCER RESEARCH (2007)
Expression of C-terminal deleted p53 isoforms in neuroblastoma
David Goldschneider et al.
NUCLEIC ACIDS RESEARCH (2006)
Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma
Tom Van Maerken et al.
CANCER RESEARCH (2006)
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
Eveline Barbieri et al.
MOLECULAR CANCER THERAPEUTICS (2006)
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastorna cells to nutlin-3-induced apoptosis
Judit Ribas et al.
EXPERIMENTAL CELL RESEARCH (2006)
Increased frequency of aberrations in the p53/MDM2/p14ARF pathway in neuroblastoma cell lines established at relapse
J Carr et al.
CANCER RESEARCH (2006)
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy
C Tovar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway
Z Zhang et al.
ONCOGENE (2005)
MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy
K Kojima et al.
BLOOD (2005)
Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels
M Li et al.
CANCER RESEARCH (2005)
The p53 pathway: positive and negative feedback loops
SL Harris et al.
ONCOGENE (2005)
Novel antisense anti-MDM2 mixed-backbone oligonucleotides:: Proof of principle, in vitro and in vivo activities, and mechanisms
RW Zhang et al.
CURRENT CANCER DRUG TARGETS (2005)
MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy
E Rayburn et al.
CURRENT CANCER DRUG TARGETS (2005)
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma
A Slack et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53
Z Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line
D Goldschneider et al.
JOURNAL OF CELL SCIENCE (2004)
Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy
Z Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The p53 pathway and its inactivation in neuroblastoma
DA Tweddle et al.
CANCER LETTERS (2003)
Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN
T Teitz et al.
ONCOGENE (2002)
Activation and activities of the p53 tumour suppressor protein
É Bálint et al.
BRITISH JOURNAL OF CANCER (2001)
p53 Cellular localization and function in neuroblastoma -: Evidence for defective G1 arrest despite WAF1 induction in MYCN-amplified cells
DA Tweddle et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells
S Sengupta et al.
EMBO JOURNAL (2000)
分享论文
